Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Abhik M Bandyopadhyay"'
Autor:
Funan He, Abhik M. Bandyopadhyay, Laura J. Klesse, Anna Rogojina, Sang H. Chun, Erin Butler, Taylor Hartshorne, Trevor Holland, Dawn Garcia, Korri Weldon, Luz-Nereida Perez Prado, Anne-Marie Langevin, Allison C. Grimes, Aaron Sugalski, Shafqat Shah, Chatchawin Assanasen, Zhao Lai, Yi Zou, Dias Kurmashev, Lin Xu, Yang Xie, Yidong Chen, Xiaojing Wang, Gail E. Tomlinson, Stephen X. Skapek, Peter J. Houghton, Raushan T. Kurmasheva, Siyuan Zheng
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Subcutaneous patient-derived xenografts (PDXs) are an important tool for childhood cancer research. Here, we describe a resource of 68 early passage PDXs established from 65 pediatric solid tumor patients. Through genomic profiling of paired
Externí odkaz:
https://doaj.org/article/7acada1d5c1a4ea691eda4a7f049f2e0
Autor:
Funan He, Abhik M. Bandyopadhyay, Laura Klesse, Anna Rogojina, Erin Butler, Taylor Hartshorne, Trevor Holland, Luz Perez Prado, Anne-Marie Langevan, Allison C. Grimes, Chatchawin Assanasen, Zhao Lai, Yi Zou, Dias Kurmashev, Lin Xu, Yang Xie, Yidong Chen, Xiaojing Wang, Gail E. Tomlinson, Stephen X. Skapek, Raushan T. Kurmasheva, Peter J. Houghton, Siyuan Zheng
Publikováno v:
Cancer Research. 83:3572-3572
Background: Cancer causes significant mortality and morbidity in children. Current therapies are effective but can cause long-term health problems for patients. Development of new therapies relies on faithful preclinical models. Patient-derived xenog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1437a5711389fb4f2319770ead63334f
https://doi.org/10.1158/1538-7445.am2023-3572
https://doi.org/10.1158/1538-7445.am2023-3572
Autor:
Abhik M Bandyopadhyay, Samson Ghilu, Edward Favours, Vanessa Del Pozo, Raushan T. Kurmasheva, Stephen W. Erickson, Malcolm A. Smith, Gerard McGeehan, Peter J. Houghton, Doris A. Phelps
Publikováno v:
Pediatr Blood Cancer
Background VTP-50469 is a potent inhibitor of the menin-MLL1 interaction and is implicated in signaling downstream of EWSR1-FLI1. Procedure VTP-50469 was evaluated against seven Ewing sarcoma (EwS) xenograft models and in vitro against EwS cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db00accf02389958ed0ca3d7e017003f
https://europepmc.org/articles/PMC10286575/
https://europepmc.org/articles/PMC10286575/
Autor:
Doris A. Phelps, Zhao Lai, Yi Chen, Malcom A. Smith, Stephen W. Erickson, Raushan T. Kurmasheva, Abhik M Bandyopadhyay, Dias Kurmashev, Andrew Joshua Robles, Peter J. Houghton
Publikováno v:
Clin Cancer Res
Purpose: Vincristine combined with camptothecin derivatives showed synergy in preclinical pediatric cancer models, and the combinations are effective in treatment of childhood solid tumors. We determined whether the synergy between vincristine and ir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b2a3dbae42b93b863a38bc9ffc74cd
https://pubmed.ncbi.nlm.nih.gov/32184294
https://pubmed.ncbi.nlm.nih.gov/32184294
Autor:
Doris A. Phelps, Cody J. Peer, Stephen W. Erickson, Malcolm A. Smith, Vanessa Del Pozo, Samson Ghilu, Abhik M Bandyopadhyay, Raushan T. Kurmasheva, William D. Figg, Edward Favours, Peter J. Houghton
Publikováno v:
Pediatric bloodcancer. 66(8)
BACKGROUND: Entinostat, a selective class I histone deacetylase inhibitor, has been reported to enhance the activity of cytotoxic agents and suppress expression of PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS). PROCEDURES: Entinostat was tested agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4716c121a30e062d5a8784f5269f12f6
https://pubmed.ncbi.nlm.nih.gov/31442007
https://pubmed.ncbi.nlm.nih.gov/31442007
Autor:
Abhik M Bandyopadhyay, Craig M. Goodwin, Krister Wennerberg, Channing J. Der, Angelina V. Vaseva, Yi Chen, Peter J. Houghton, Kris C. Wood, Vanessa Del Pozo, Prson Gautam
Publikováno v:
Cancer Research. 80:A54-A54
RAS pathway mutations are found in nearly 75% of high-risk embryonal rhabdomyosarcoma (ERMS). While RAS oncoproteins are well-established therapeutic targets for many adult human cancers, still very little is known about the role of RAS mutations in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::919989380fc1cbbb14beb969a8a244ab
https://doi.org/10.1158/1538-7445.pedca19-a54
https://doi.org/10.1158/1538-7445.pedca19-a54